bemnifosbuvir
bemnifosbuvir: developed by 1 company · 2 clinical trials tracked.
bemnifosbuvir evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could bemnifosbuvir → AVIR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) Chronic Hepatitis C Virus | Phase 3 |
Clinical Trials (2)
A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
Primary endpoint: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Primary endpoint: Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause
Frequently asked questions
Who is developing bemnifosbuvir?
bemnifosbuvir is being developed by Atea Pharmaceuticals, Inc..
How many clinical trials involve bemnifosbuvir?
BioSniper tracks 2 clinical trials involving bemnifosbuvir.